文献速递淋巴瘤

基于基因表达的特征可预测成人T细胞淋巴母细胞淋巴瘤生存:一项多中心研究

A gene-expression-based signature predicts survival in adults with T-cell lymphoblastic lymphoma: a multicenter study.
PubMed 文献 · Leukemia · 2020-02-20

本研究通过比较进展与未进展T-LBL患者的基因表达谱,识别43个差异mRNA,并基于LASSO Cox回归建立11基因分类器。在训练队列(n=169)中,高风险患者PFS(HR 4.123,95%CI 2.565-6.628;p<0.001)、DFS(HR 3.148,95%CI 1.857-5.339;p<0.001)和OS(HR 3.790,95%CI 2.237-6.423;p<0.001)显著低于低风险患者,并在内部测试和独立验证队列中验证。包含分类器、LDH、ECOG-PS、CNS受累和NOTCH1/FBXW7状态的列线图预测准确性优于单一变量,且列线图评分≥154.2的患者显著受益于BFM方案。

要点

  • 11基因分类器可区分T-LBL患者进展风险,高风险者PFS、DFS、OS显著更差。
  • 结合分类器、LDH、ECOG-PS、CNS受累和NOTCH1/FBXW7的列线图预测准确性更高。
  • 列线图评分≥154.2的患者从BFM方案中显著获益。

核心结论

  • 基于11基因分类器的列线图有助于T-LBL个体化预后预测和治疗决策。

研究设计与样本

  • 多中心研究,探索进展(n=22)与未进展(n=28)T-LBL患者基因表达谱,识别43个差异mRNA,基于LASSO Cox回归和NanoString定量建立11基因分类器,在训练队列(n=169)、内部测试队列(n=84)和独立验证队列(n=360)中评估。

主要发现

  • 训练队列中高风险患者较低风险患者PFS(HR 4.123,95%CI 2.565-6.628;p<0.001)、DFS(HR 3.148,95%CI 1.857-5.339;p<0.001)和OS(HR 3.790,95%CI 2.237-6.423;p<0.001)显著更差。
  • 分类器预后准确性在内部测试和独立验证队列中得到验证。
  • 包含分类器、LDH、ECOG-PS、CNS受累和NOTCH1/FBXW7状态的列线图预测准确性显著优于单一变量。
  • 添加5-miRNA特征进一步提高了列线图准确性。
  • 列线图评分≥154.2的患者显著受益于BFM方案。

关键数值与推荐

  • 11基因分类器基于LASSO Cox回归建立,使用NanoString定量。
  • 列线图包含五个独立变量:分类器、LDH水平、ECOG-PS、CNS受累和NOTCH1/FBXW7状态。
  • 列线图评分阈值154.2用于识别BFM方案获益人群。

临床怎么用

  • 可利用11基因分类器对成人T-LBL患者进行风险分层。
  • 结合列线图评分(含分类器、LDH、ECOG-PS、CNS受累和NOTCH1/FBXW7状态)辅助预后预测。
  • 列线图评分≥154.2的患者可考虑BFM方案治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We aimed to establish a discriminative gene-expression-based classifier to predict survival outcomes of T-cell lymphoblastic lymphoma (T-LBL) patients. After exploring global gene-expression profiles of progressive (n = 22) vs. progression-free (n = 28) T-LBL patients, 43 differentially expressed mRNAs were identified. Then an eleven-gene-based classifier was established using LASSO Cox regression based on NanoString quantification. In the training cohort (n = 169), high-risk patients stratified using the classifier had significantly lower progression-free survival (PFS: hazards ratio 4.123, 95% CI 2.565-6.628; p < 0.001), disease-free survival (DFS: HR 3.148, 95% CI 1.857-5.339; p < 0.001), and overall survival (OS: HR 3.790, 95% CI 2.237-6.423; p < 0.001) compared with low-risk patients. The prognostic accuracy of the classifier was validated in the internal testing (n = 84) and independent validation cohorts (n = 360). A prognostic nomogram consisting of five independent variables including the classifier, lactate dehydrogenase levels, ECOG-PS, central nervous system involvement, and NOTCH1/FBXW7 status showed significantly greater prognostic accuracy than each single variable alone. The addition of a five-miRNA-based signature further enhanced the accuracy of this nomogram. Furthermore, patients with a nomogram score ≥154.2 significantly benefited from the BFM protocol. In conclusion, our nomogram comprising the 11-gene-based classifier may make contributions to individual prognosis prediction and treatment decision-making.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Tian XP, Xie D, Huang WJ, et al. A gene-expression-based signature predicts survival in adults with T-cell lymphoblastic lymphoma: a multicenter study. Leukemia. 2020. PMID: 32080345. doi:10.1038/s41375-020-0757-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。